Quick Answer
Lyell Immunopharma, Inc. reported Stockholders Equity of $248.20 million for fiscal year 2025.
Lyell Immunopharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $248.20M | -35.2% |
| 2024 | $382.82M | -41.5% |
| 2023 | $654.95M | -21.4% |
| 2022 | $833.25M | -10.4% |
| 2021 | $929.79M | +417.8% |
| 2020 | -$292.53M | -163.3% |
| 2019 | -$111.11M | -13171.5% |
| 2018 | $850.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $329.12M | -38.0% | +10.1% |
| June 30, 2025 | $298.92M | -47.2% | -11.2% |
| March 31, 2025 | $336.52M | -44.2% | -12.1% |
| December 31, 2024 | $382.82M | -41.5% | -27.9% |
| September 30, 2024 | $530.70M | -23.9% | -6.3% |
| June 30, 2024 | $566.50M | -23.1% | -6.1% |
| March 31, 2024 | $603.16M | -23.0% | -7.9% |
| December 31, 2023 | $654.95M | -21.4% | -6.1% |
- Lyell Immunopharma, Inc. showed a decrease of -35.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Lyell Immunopharma, Inc.’s stockholders equity has grown by 29100.2% (from $850.0 thousand to $248.20 million).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: